Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564068 | 0.92 | MAOB (0.56) | MAOBMAOAPOLBMAPTNPC1 | |
| SCHEMBL14117266 | 0.88 | MAOB (0.60) | MAOBMAOANPC1RAB9AMEN1 | |
| SCHEMBL16742764 | 0.87 | MAOA (0.43) | MAOBMAOAALOX5POLBMAPT | |
| SCHEMBL14117265 | 0.87 | MAOB (0.66) | MAOBMAOAPOLBMAPT | |
| SCHEMBL30398935 | 0.87 | MAOB (0.66) | MAOBMAOAPOLBMAPT | |
| SCHEMBL4446845 | 0.86 | ERN1 (0.58) | MAOBMAOACCNB2CDK1CDK4 | |
| SCHEMBL1564070 | 0.86 | CCNB2 (0.46) | MAOBMAOAPOLBMAPTNPC1 | |
| SCHEMBL8327914 | 0.85 | MAOA (0.61) | MAOBMAOAALOX5POLBMAPT | |
| SCHEMBL28489661 | 0.84 | MAOB (0.63) | MAOBMAOAPOLBMAPT | |
| SCHEMBL28482963 | 0.84 | MAOB (0.63) | MAOBMAOAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-20230074558-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2022-11-17 | — | — | US | disclosed |
| EP-4069683-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | Mersana Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-108707140-B | Protease C inhibitors | 勃林格殷格翰国际有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2021-06-15 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-6740676-B2 | TREATING DISEASES CONTROLLED BY OR RESPONSIVE TO RETINOIC ACID | ALLERGAN, INC. | 2004-05-25 | — | — | US | disclosed |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | ALLERGAN, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030191181-A1 | 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003080594-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | ALLERGAN, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191181-A1 | 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | MAOB 1115/4885MAOA 483/4885ALOX5 264/4885 |
| US-20230310373-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSG, CTSZ | MAOB 924/4885MAOA 699/4885ALOX5 832/4885 |
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, OXER1, IL1B | MAOB 2128/4885MAOA 3299/4885ALOX5 94/4885 |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | RARA, CYP2R1, RXRA | MAOB 616/4885MAOA 299/4885ALOX5 227/4885 |
| US-20230074558-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | STING1, CGAS, MAVS | MAOB 3455/4885MAOA 3798/4885ALOX5 3287/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAOB 4027/4885MAOA 4312/4885ALOX5 3343/4885 |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | OXER1, CASP1, IL6 | MAOB 2182/4885MAOA 3304/4885ALOX5 102/4885 |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | MAOB 660/4885MAOA 191/4885ALOX5 732/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | MAOB 2381/4885MAOA 3529/4885ALOX5 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.